IN8BIO, INC. (INAB)
D
Pipeline Grade
Financial Position (from SEC Filings)
$22.2M
Cash & Equivalents
$5.0M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$13M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-01 | Phase1 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx)... | PHASE2 | Active Not Recruiting | 4 |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc... | PHASE1 | Recruiting | 38 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.